Key Developments: Becton Dickinson and Co (BDX)

BDX on New York Consolidated

115.01USD
18 Sep 2014
Price Change (% chg)

$0.49 (+0.43%)
Prev Close
$114.52
Open
$114.74
Day's High
$115.21
Day's Low
$114.65
Volume
828,254
Avg. Vol
639,708
52-wk High
$120.66
52-wk Low
$98.30

Search Stocks

Latest Key Developments (Source: Significant Developments)

Becton Dickinson And Co reaffirms FY 2014 revenue guidance; gives FY 2014 earnings guidance - Conference Call
Wednesday, 15 Jan 2014 02:00pm EST 

Becton Dickinson And Co:Says for FY 2014, it expects revenue growth of between 4 pct - 5pct, which assumes the macroeconomic environment remains fairly stable as compared to last year.Says FY 2014 it anticipates underlying earnings growth of 9 pct to 10 pct.The company reported revenues of $8.1 billion in FY 2013.FY 2014 revenue of $8.4 billion, EPS of $6.22, net income of $1.2 million and EBITDA of $2.2 million - Thomson Reuters I/B/E/S.  Full Article

Becton Dickinson And Co Increases Dividend
Tuesday, 26 Nov 2013 08:00am EST 

Becton Dickinson And Co:Says it has declared a quarterly dividend of 54.5 cents per common share, an increase of 5 cents per share, or about 10 percent, from the previous quarter.Says the dividend will be payable on Dec. 31 to holders of record on Dec.10.  Full Article

Becton Dickinson And Co Issues FY 2014 Mixed Guidance; Plans To Repurchase About $450 Million Of Common Stock
Tuesday, 5 Nov 2013 06:00am EST 

Becton Dickinson And Co announced that it estimates that reported and currency-neutral revenues for fiscal 2014 will increase 4.0% to 5.0%. The Company expects reported diluted earnings per share from continuing operations for fiscal 2014 to be between $6.16 and $6.22. On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 8.5% to 9.5%, or 9.0% to 10.0% excluding the incremental impact of the medical device tax. The Company plans to repurchase, subject to market conditions, about $450 million of its common stock in 2014. The Company reported revenues of $8.1 billion in fiscal 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $8.3 billion and EPS of $6.27 for fiscal 2014.  Full Article

Becton Dickinson And Co's Subsidiary Announces FDA Approval Of Injectable For Pain Management
Monday, 4 Nov 2013 12:40pm EST 

BD Rx Inc., a wholly-owned subsidiary of global medical technology company Becton, Dickinson and Company (BD), announced that the U.S. Food and Drug Administration (FDA) has approved Morphine Sulfate Injection, USP to be offered in the BD Simplist line of ready-to-administer prefilled injectables in the common strengths: 2mg/mL, 4mg/mL, 5mg/mL, 8mg/mL and 10mg/mL. Morphine Sulfate Injection, USP is indicated for the management of pain not responsive to non-narcotic analgesics. BD Rx will begin production of morphine immediately and projects initial product availability in early calendar year 2014.  Full Article

Sartorius Stedim Biotech SA And Becton Dickinson And Co's BD Diagnostics Strengthen Cooperation In The Area Of Microbiological Diagnostics
Wednesday, 16 Oct 2013 03:00am EDT 

Sartorius Stedim Biotech SA and BD Diagnostics, a segment of Becton Dickinson And Co, announced a collaboration to develop, manufacture and market various ready-to-use, prefilled media products for microbiological applications in pharmaceutical, biotech and research laboratories. As part of this strategic collaboration, BD will fill special SSB single-use products with BD culture media and supply these to SSB as prepackaged products. In addition, the companies are exploring options of extending their existing business relationship by pursuing further solutions in the field of microbiological diagnostics.  Full Article

Becton Dickinson And Co Reaffirms FY 2013 Guidance
Thursday, 1 Aug 2013 06:01am EDT 

Becton Dickinson And Co reaffirmed its previously communicated guidance for fiscal 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to approach 5.0%, which is the upper end of the Company's previously communicated guidance range. Reported revenue growth is expected to be between 3.5% to 4.0%. Earnings per share from continuing operations for fiscal 2013 are expected to be between $5.65 and $5.68, or $5.72 and $5.75 after adjusting for a pending antitrust class action settlement. This represents growth of 6.5% to 7.0% over 2012 adjusted diluted earnings per share of $5.37, which excludes a pension settlement charge, in fiscal year 2012. On a currency-neutral basis, adjusted earnings per share growth is expected to be between 8.5 to 9.0%. After adjusting for the impact of the medical device excise tax and foreign currency, adjusted diluted earnings per share are expected to grow at the upper end of the Company's previously communicated guidance range of 11.0% to 11.5%. In line with previously disclosed guidance, the Company plans to repurchase, subject to market conditions, up to $500 million of its common stock in fiscal year 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $7.99 billion and EPS of $5.74 for fiscal 2013.  Full Article

Becton Dickinson And Co's BD Diagnostics and College Of American Pathologists Announce Strategic Alliance To Support Laboratory And Performance In India And China
Tuesday, 30 Jul 2013 01:23pm EDT 

BD Diagnostics, a segment of Becton Dickinson And Co, a global medical technology company, and the College of American Pathologists (CAP), announced the launch of a new strategic alliance that will provide solutions to advance laboratory for improved patient outcomes in China and India. BD and CAP announced the collaboration during the American Association for Clinical Chemistry (AACC) Annual Meeting in Houston, Texas.  Full Article

Becton Dickinson And Co Declares Dividend
Tuesday, 23 Jul 2013 12:40pm EDT 

Becton Dickinson And Co announced that Board of Directors has declared a quarterly dividend of 49.5 cents per common share, payable on September 30, 2013 to holders of record on September 9, 2013.  Full Article

Becton Dickinson And Co Appoints New CFO
Monday, 8 Jul 2013 08:00am EDT 

Becton, Dickinson and Company announced that the appointment of Christopher Reidy as Chief Financial Officer and Executive Vice President of Administration, effective July 15, 2013. Mr. Reidy will report to Vincent A. Forlenza, Chairman, Chief Executive Officer and President.  Full Article

Becton Dickinson And Co Declares Dividend
Tuesday, 21 May 2013 11:25am EDT 

Becton Dickinson And Co announced that it has declared a quarterly dividend of 49.5 cents per common share, payable on June 28, 2013 to holders of record on June 7, 2013. The indicated annual dividend rate is $1.98 per share.  Full Article

Search Stocks